Clinical trials sponsored by Beijing InnoCare Pharma Tech Co., Ltd.

Phase breakdown

Conditions studied

Recruiting trials led by Beijing InnoCare Pharma Tech Co., Ltd.

• Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
  NCT07251998 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
  NCT06842199 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 46 locations
• Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
  NCT07440537 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 27 locations
• Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
  NCT05688696 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 41 locations
• ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
  NCT06775860 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 62 locations

Common questions

How many trials is Beijing InnoCare Pharma Tech Co., Ltd. recruiting for?

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 5 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.